 FDA is still reviewing the available information and has not concluded that carbidopa/levodopa/entacapone increases the risk of developing prostate cancer.Healthcare professionals were advised to be aware of this possible risk and follow current guidelines for prostate cancer screening.FDA recommended that healthcare professionals follow the recommendations in the drug label when prescribing carbidopa/levodopa/entacapone and Comtan.